8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Apr 2, 2026·SEC
Vanda Pharmaceuticals Inc.(VNDA)Earnings, Financials & Key Ratios
VNDA•NASDAQ
$6.39
Price updated Jul 7, 2026
AboutVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Show more
- Revenue$216M+8.7%
- EBITDA-$139M-328.1%
- Net Income-$220M-1066.5%
- EPS (Diluted)-3.74-1068.8%
- Gross Margin93.96%-0.4%
- EBITDA Margin-64.44%-293.8%
- Operating Margin-69.95%-242.0%
- Net Margin-102.02%-973.0%
- ROE-50.93%-1359.9%
VNDA Price & Volume
Vanda Pharmaceuticals Inc. (VNDA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Threaten Long-term Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Patent Litigation and Exclusivity
Key Thesis Takeaways
- Vanda Pharmaceuticals faces a challenging outlook characterized by inconsistent revenue growth and an aggressive, capital-intensive litigation strategy that continues to erode shareholder equity.
- While the company maintains high gross margins near 93%, these are insufficient to offset surging SG&A expenses, which reached $68.4 million in 2026Q1.
- Investors should remain cautious as the company's cash reserves have dwindled to $54.0 million, raising significant concerns regarding the sustainability of its current business model and long-term liquidity.
Verdict Logic
the company's cash position has declined by approximately 60% since 2023Q4 to $54.0 million, suggesting that the current burn rate is unsustainable without a fundamental shift in operational strategy.
VNDA Growth Metrics
Vanda Pharmaceuticals Inc. (VNDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6.99%
5 Years-2.73%
3 Years-5.29%
TTM8.16%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-441.37%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-437.49%
Return on Capital
10 Years-3.36%
5 Years-6.73%
3 Years-14.47%
Last Year-33.59%
VNDA Recent Earnings
Vanda Pharmaceuticals Inc. (VNDA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.82-54.7%
$0.53
Rev
$52M-5.9%
$55M
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$0.46+78.9%
$2.18
Rev
$57M-3.5%
$59M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.38-22.6%
$0.31
Rev
$56M-5.1%
$59M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.46-35.3%
$0.34
Rev
$53M-10.5%
$59M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.82vs $0.53-54.7% | $52Mvs $55M-5.9% |
| Q1 2026 | Feb 11, 2026 | $0.46vs $2.18+78.9% | $57Mvs $59M-3.5% |
| Q4 2025 | Oct 29, 2025 | $0.38vs $0.31-22.6% | $56Mvs $59M-5.1% |
| Q3 2025 | Jul 31, 2025 | $0.46vs $0.34-35.3% | $53Mvs $59M-10.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Vanda Pharmaceuticals Inc. (VNDA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.39 | $377.7M | -1.71 | 8.72% | -102.02% | -50.93% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $25.82 | $1.02B | 161.38 | 3.63% | 1.27% | 1.31% | — |
Compare VNDA vs Peers
Vanda Pharmaceuticals Inc. (VNDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VNDA SEC Filings & Documents
Vanda Pharmaceuticals Inc. (VNDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when VNDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VNDA Frequently Asked Questions
Vanda Pharmaceuticals Inc. (VNDA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Vanda Pharmaceuticals Inc.'s revenue?
Vanda Pharmaceuticals Inc. (VNDA) reported $217.8M in revenue for fiscal year 2025. This represents a 640812% increase from $0.0M in 2004.
How fast is Vanda Pharmaceuticals Inc. growing?
Vanda Pharmaceuticals Inc. (VNDA) grew revenue by 8.7% over the past year. This is steady growth.
Is VNDA profitable?
Vanda Pharmaceuticals Inc. (VNDA) reported a net loss of $239.5M for fiscal year 2025.
Dividend & Returns
What is VNDA's return on equity?
Vanda Pharmaceuticals Inc. (VNDA) has a return on equity (ROE) of -50.9%. Negative ROE indicates the company is unprofitable.
What is Vanda Pharmaceuticals Inc.'s free cash flow?
Vanda Pharmaceuticals Inc. (VNDA) had negative free cash flow of $127.3M in fiscal year 2025, likely due to heavy capital investments.